23 October 2015 -  In accordance with the pCODR Procedures, the pCODR Provincial Advisory Group requested additional information on pembrolizumab and (Keytruda) and nivolumab (Opdivo) which extend beyond the submitted scope of the review.

For more details, go to: https://www.cadth.ca/keytruda-metastatic-melanoma-details